Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies

Area of Science:

• Immunodermatology
• Skin Barrier Research
• Atopic Dermatitis Pathogenesis

Background:

• Atopic dermatitis (AD) is a chronic skin condition characterized by severe itching, eczema, and skin barrier dysfunction.
• Reduced filaggrin expression contributes to impaired skin barrier function in AD patients.
• Lesional skin in AD shows Th2 and Th22 immune responses, which worsen with chronicity.

Purpose of the Study:

• To explore the role of the thymic stromal lymphopoietin (TSLP)/Th2/Th22 pathway in AD pathogenesis.
• To investigate potential therapeutic targets for atopic dermatitis.
• To evaluate strategies for restoring skin barrier function in AD.

Main Methods:

• Analysis of immune responses in lesional skin of atopic dermatitis patients.
• Investigation of the ORAI1 calcium channel's role in TSLP release.
• Evaluation of TSLP, Th2, and Th22 cytokines in disease chronicity and itch.
• Consideration of filaggrin expression modulation for barrier repair.

Main Results:

• TSLP release, triggered by ORAI1 channel activation, initiates Th2 and Th22 immune responses.
• Th2-derived interleukin-31 and TSLP contribute to the itch sensation in AD.
• IgE autoreactivity may play a role in the chronicity of atopic dermatitis.

Conclusions:

• The TSLP/Th2/Th22 pathway represents a promising therapeutic target for atopic dermatitis.
• Enhancing filaggrin expression, potentially via aryl hydrocarbon receptor ligands, could be an adjunctive strategy to repair the skin barrier in AD.